{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T08:51:00Z","timestamp":1781945460979,"version":"3.54.5"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009659","name":"Guangzhou Medical University","doi-asserted-by":"publisher","award":["2024SRP020"],"award-info":[{"award-number":["2024SRP020"]}],"id":[{"id":"10.13039\/100009659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.bmcl.2025.130507","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T23:35:02Z","timestamp":1765668902000},"page":"130507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["N-[3-(4-(2-methoxyphenyl) piperazine-1-yl) propyl]-heteroaromatic carboxamide as selective \u03b11A\/1D-adrenoceptor antagonists: SAR study and metabolic stability evaluation"],"prefix":"10.1016","volume":"133","author":[{"given":"Ruxia","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linxin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Ohwada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2025.130507_bb0005","doi-asserted-by":"crossref","first-page":"16031","DOI":"10.1038\/nrdp.2016.31","article-title":"Benign prostatic hyperplasia","volume":"2","author":"Chughtai","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.bmcl.2025.130507_bb0010","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/bju.15229","article-title":"Benign prostatic hyperplasia \u2013 what do we know?","volume":"127","author":"Devlin","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.bmcl.2025.130507_bb0015","first-page":"223","article-title":"Benign prostatic hyperplasia","volume":"46","author":"Langan","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.bmcl.2025.130507_bb0020","article-title":"Orthostatic hypotension in benign prostatic hyperplasia patients and its association with alpha-1 antagonist use: a comprehensive literature review","volume":"25","author":"Abubakar","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.bmcl.2025.130507_bb0025","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0022-5347(17)35544-1","article-title":"Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate","volume":"150","author":"Price","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.bmcl.2025.130507_bb0030","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00345-002-0246-7","article-title":"Tamsulosin: an overview","volume":"19","author":"Chapple","year":"2002","journal-title":"World J Urol"},{"key":"10.1016\/j.bmcl.2025.130507_bb0035","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/CIA.S13803","article-title":"Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia","author":"Yoshida","year":"2011","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.bmcl.2025.130507_bb0040","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejmech.2015.04.005","article-title":"Novel naftopidil-related derivatives and their biological effects as alpha1-adrenoceptors antagonists and antiproliferative agents","volume":"96","author":"Huang","year":"2015","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130507_bb0045","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ejphar.2016.09.009","article-title":"Pharmaceutical evaluation of naftopidil enantiomers: rat functional assays in vitro and estrogen\/androgen induced rat benign prostatic hyperplasia model in vivo","volume":"791","author":"Huang","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bmcl.2025.130507_bb0050","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.apsb.2017.04.011","article-title":"Crystal structures, absolute configurations and molecular docking studies of naftopidil enantiomers as \u03b1 1D -adrenoceptor antagonists","volume":"7","author":"Xu","year":"2017","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.bmcl.2025.130507_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2022.106117","article-title":"Naftopidil enantiomers suppress androgen accumulation and induce cell apoptosis via the UDP-glucuronosyltransferase 2B15 in benign prostate hyperplasia","volume":"221","author":"Zhan","year":"2022","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.bmcl.2025.130507_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019695","article-title":"A novel structural framework for \u03b11A\/D-adrenoceptor selective antagonists identified using subtype selective pharmacophores. Fraternali F, ed","volume":"6","author":"Stoddart","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bmcl.2025.130507_bb0065","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jmgm.2010.05.002","article-title":"Ligand-based pharmacophore model of N-aryl and N-Heteroaryl piperazine \u03b11A-adrenoceptors antagonists using GALAHAD","volume":"29","author":"Zhao","year":"2010","journal-title":"J Mol Graph Model"},{"key":"10.1016\/j.bmcl.2025.130507_bb0070","article-title":"Discovery of an enantiopure N-[2-hydroxy-3-phenyl piperazine propyl]-aromatic carboxamide derivative as highly selective \u03b11D\/1A-adrenoceptor antagonist and homology modelling","author":"Huang","year":"2024","journal-title":"Chin Chem Lett"},{"key":"10.1016\/j.bmcl.2025.130507_bb0075","doi-asserted-by":"crossref","first-page":"9489","DOI":"10.1021\/acs.jmedchem.6b01217","article-title":"Design, synthesis, and biological evaluation of novel Tetrahydroprotoberberine derivatives (THPBs) as selective \u03b1 1A -adrenoceptor antagonists","volume":"59","author":"Guo","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130507_bb0080","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1021\/acs.jmedchem.5b02023","article-title":"Design, synthesis, and biological evaluation of Indoline and indole derivatives as potent and selective \u03b1 1A -adrenoceptor antagonists","volume":"59","author":"Zhao","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130507_bb0085","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.bjp.0700907","article-title":"The effects of tamsulosin, a high affinity antagonist at functional \u03b1 1A - and \u03b1 1D -adrenoceptor subtypes: Tamsulosin and functional \u03b1 1 -adrenoceptors","volume":"120","author":"Noble","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bmcl.2025.130507_bb0090","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1038\/s41467-023-39310-x","article-title":"Structural basis of \u03b11A-adrenergic receptor activation and recognition by an extracellular nanobody","volume":"14","author":"Toyoda","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmcl.2025.130507_bb0095","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41467-021-27911-3","article-title":"Crystal structure of the \u03b11B-adrenergic receptor reveals molecular determinants of selective ligand recognition","volume":"13","author":"Deluigi","year":"2022","journal-title":"Nat Commun"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25004160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25004160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T08:22:14Z","timestamp":1781943734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X25004160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":19,"alternative-id":["S0960894X25004160"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130507","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"N-[3-(4-(2-methoxyphenyl) piperazine-1-yl) propyl]-heteroaromatic carboxamide as selective \u03b11A\/1D-adrenoceptor antagonists: SAR study and metabolic stability evaluation","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130507","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130507"}}